Floatz Rating
B62/100
Confidence
Indicative
Sponsor
University Hospital, Bordeaux
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07145125CT.gov Real-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL-R2-B2) | — | Completed | — | — | — |
NCT06761911CT.gov BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT06170489CT.gov A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL) | — | Recruiting | — | — | — |
NCT05757466CT.gov Prolgolimab Monotherapy or in Combination With Bendamustine for r/r Classical Hodgkin Lymphoma | — | Unknown | — | — | — |
NCT05508867CT.gov A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) | — | Completed | — | — | — |
NCT05352828CT.gov Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy | — | Active Not Recruiting | — | — | — |
NCT04268706CT.gov Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) | — | Active Not Recruiting | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT03755804CT.gov Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 | — | Active Not Recruiting | — | — | — |
NCT03524235CT.gov Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL | — | Completed | — | — | — |
Show 10 more trialsShow fewer
NCT02927769CT.gov A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment | — | Completed | — | — | — |
NCT02240719CT.gov Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer | — | Completed | — | — | — |
NCT02168140CT.gov CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | — | Completed | — | — | — |
NCT02059239CT.gov Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma | — | Completed | — | — | — |
NCT01900509CT.gov Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies | — | Completed | — | — | — |
NCT01874054CT.gov Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01716806CT.gov A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | — | Completed | — | — | — |
NCT01657331CT.gov Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) | — | Completed | — | — | — |
NCT01326702CT.gov Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | — | Completed | — | — | — |
NCT03914885CT.gov Compassionate Use Re-Infusion of ATLCAR.CD30 | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hodgkins Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bendamustine (this asset) | University Hospital, Bordeaux | Approved | B · 62 |
| Everolimus | OHSU Knight Cancer Institute | P2 | BBB |
| Camustine | VIVUS LLC | P2 | BBB |
| Carboplatin | St. Petersburg State Pavlov Medical University | P2 | BBB |
| Cyclosporin A | City of Hope Medical Center | P3 | BBB |
| Isocyclophosphamide | St. Petersburg State Pavlov Medical University | P3 | BBB |
| Irinotecan | OHSU Knight Cancer Institute | P2 | BBB |
| Vinblastine | M.D. Anderson Cancer Center | P4 | BBB |
| Vinorelbine Ditartrate | Michael Spinner, MD | P3 | BBB |
+42 more in the Hodgkins Lymphoma cohort
Other indications for Bendamustine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Hodgkin Lymphoma | — | P3 | BB · 70 |
| B-Cell Chronic Lymphocytic Leukemia | — | P3 | BB · 70 |
| Follicular Lymphoma | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bendamustine in Hodgkins Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bendamustine-hodgkins-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →